IL164295A0 - Tri-substituted heteroaryls and methods of making and using the same - Google Patents
Tri-substituted heteroaryls and methods of making and using the sameInfo
- Publication number
- IL164295A0 IL164295A0 IL16429503A IL16429503A IL164295A0 IL 164295 A0 IL164295 A0 IL 164295A0 IL 16429503 A IL16429503 A IL 16429503A IL 16429503 A IL16429503 A IL 16429503A IL 164295 A0 IL164295 A0 IL 164295A0
- Authority
- IL
- Israel
- Prior art keywords
- tri
- making
- methods
- same
- substituted heteroaryls
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36979302P | 2002-04-04 | 2002-04-04 | |
PCT/US2003/010440 WO2003087304A2 (en) | 2002-04-04 | 2003-04-04 | Tri-substituted heteroaryls and methods of making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
IL164295A0 true IL164295A0 (en) | 2005-12-18 |
Family
ID=29250467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16429503A IL164295A0 (en) | 2002-04-04 | 2003-04-04 | Tri-substituted heteroaryls and methods of making and using the same |
Country Status (19)
Country | Link |
---|---|
US (1) | US7612094B2 (xx) |
EP (1) | EP1499308A4 (xx) |
JP (1) | JP2005527590A (xx) |
KR (1) | KR20040094908A (xx) |
CN (1) | CN100448868C (xx) |
AR (1) | AR039241A1 (xx) |
AU (1) | AU2003228446B2 (xx) |
CA (1) | CA2480860A1 (xx) |
EA (1) | EA010418B1 (xx) |
IL (1) | IL164295A0 (xx) |
IS (1) | IS7475A (xx) |
MX (1) | MXPA04009546A (xx) |
NO (1) | NO20044779L (xx) |
NZ (1) | NZ536202A (xx) |
PL (1) | PL373502A1 (xx) |
RS (1) | RS95904A (xx) |
UA (1) | UA81624C2 (xx) |
WO (1) | WO2003087304A2 (xx) |
ZA (1) | ZA200407902B (xx) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0217787D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | C ompounds |
KR20050057415A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인코포레이티드 | 전환성장인자(tgf) 억제제로서의 신규한 싸이아졸 및 옥사졸 화합물 |
AP2005003264A0 (en) * | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGD) inhibitors. |
AU2003259475A1 (en) | 2002-09-18 | 2004-04-08 | Pfizer Products Inc. | Pyrazole derivatives as transforming growth factor (TGF) inhibitors |
CA2497971A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Triazole derivatives as transforming growth factor (tgf) inhibitors |
PL375973A1 (en) | 2002-09-18 | 2005-12-12 | Pfizer Products Inc. | Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors |
PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
BRPI0417213A (pt) * | 2003-12-24 | 2007-02-06 | Scios Inc | tratamento de gliomas malìgnos com inibidores de tgf-beta |
MY146532A (en) * | 2004-03-05 | 2012-08-15 | Taisho Pharmaceutical Co Ltd | Thiazole derivative |
US20080319012A1 (en) | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
CA2578630A1 (en) * | 2004-08-31 | 2006-03-09 | Wen-Cherng Lee | Pyrimidinylimidazoles as tgf-beta inhibitors |
EP1798229A4 (en) * | 2004-09-07 | 2009-07-29 | Sankyo Co | SUBSTITUTED BIPHENYL DERIVATIVE |
AU2005289887A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
JP2008516962A (ja) * | 2004-10-15 | 2008-05-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管傷害を治療する方法 |
GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
US20100166819A1 (en) | 2005-12-22 | 2010-07-01 | Biogen Idec Ma Inc. A Corporation | Transforming Growth Factor Modulators |
DK2083863T3 (da) | 2006-10-03 | 2015-06-22 | Genzyme Corp | Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
WO2009009059A1 (en) * | 2007-07-09 | 2009-01-15 | Biogen Idec Ma Inc. | Spiro compounds as antagonists of tgf-beta |
US8138168B1 (en) | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
BRPI0908906A2 (pt) * | 2008-03-21 | 2019-09-24 | Novartis Ag | compostos heterocíclicos e usos dos mesmos |
US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
CL2009000904A1 (es) | 2008-04-21 | 2010-04-30 | Shionogi & Co | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. |
UA103319C2 (xx) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Сполуки бензенсульфонамідтіазолу та -оксазолу$соединения бензенсульфонамидтиазола и -оксазола |
JP2011521969A (ja) * | 2008-05-30 | 2011-07-28 | スムマ ヘルス システムズ エルエルシー | 眼疾患を治療するためのTGF−β受容体阻害剤又はアクチビン様キナーゼ(ALK)5阻害剤、A−83−01及びSB−431542の使用方法及び創傷治療条件 |
WO2010011917A1 (en) * | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | SEH AND 11β-HSD1 DUAL INHIBITORS |
CN102695511A (zh) * | 2009-04-17 | 2012-09-26 | 舒玛健康***有限责任公司 | 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途 |
US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
CA2841252C (en) | 2011-07-13 | 2019-02-26 | Sk Chemicals Co., Ltd. | 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
AU2011379972B2 (en) | 2011-10-26 | 2016-05-12 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
WO2014151871A2 (en) | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
DK3104847T3 (da) | 2014-02-07 | 2021-02-01 | Tamogatott Kutatocsoportok Irodaja | Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser |
US10842794B2 (en) | 2014-02-07 | 2020-11-24 | Támogatott Kutatócsoportok Irodája | Use of Sigma-1 receptor agonist compounds |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
US20210154188A1 (en) * | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
JP2021530554A (ja) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤 |
KR20210111313A (ko) * | 2019-01-22 | 2021-09-10 | 주식회사 비씨켐 | 에이엘케이4/5 억제제인 융합된 고리 헤테로아릴 화합물 |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
KR20230051500A (ko) | 2020-07-15 | 2023-04-18 | 키에시 파르마슈티시 엣스. 피. 에이. | Alk5 억제제로서 피리다진일 아미노 유도체 |
EP4182322B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
MX2023000519A (es) | 2020-07-15 | 2023-02-13 | Chiesi Farm Spa | Derivados de pirido-oxazina-amino como inhibidores de alk5. |
WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
CN112759592A (zh) * | 2021-02-01 | 2021-05-07 | 无锡鸣鹭医药科技有限公司 | 一种6-碘[1,2,3]***并[1,5-a]吡啶的合成方法 |
CN114105975A (zh) * | 2021-02-25 | 2022-03-01 | 无锡海伦生物科技有限公司 | 一种[1,2,4]三氮唑[1,5-a]吡啶-6-甲醛的合成方法 |
WO2023046698A1 (en) | 2021-09-21 | 2023-03-30 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3940486A (en) * | 1971-05-10 | 1976-02-24 | Ciba-Geigy Corporation | Imidazole derivatives in the treatment of pain |
US4302464A (en) | 1980-10-16 | 1981-11-24 | Pfizer Inc. | Imidazolylpyridine therapeutic agents |
IL101291A0 (en) * | 1991-03-22 | 1992-11-15 | Nippon Soda Co | 2-pyridine derivatives,their preparation and their use as fungicides |
IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
US5656644A (en) * | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
US5916891A (en) * | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
DK64592D0 (da) * | 1992-05-14 | 1992-05-14 | Carlbiotech Ltd As | Peptider til terapeutisk behandling |
US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
US5593991A (en) * | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
US6369068B1 (en) * | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
US5739143A (en) * | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US5854276A (en) | 1995-06-29 | 1998-12-29 | Fujisawa Pharmaceutical Co., Ltd. | Substance WF16616, process for production thereof, and use thereof |
US5837719A (en) | 1995-08-10 | 1998-11-17 | Merck & Co., Inc. | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US5792778A (en) * | 1995-08-10 | 1998-08-11 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
US6083949A (en) | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
ZA9610687B (en) * | 1995-12-22 | 1997-09-29 | Smithkline Beecham Corp | Novel synthesis. |
US6046208A (en) * | 1996-01-11 | 2000-04-04 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US5756499A (en) * | 1996-01-11 | 1998-05-26 | Smithkline Beecham Corporation | Substituted imidazole compounds |
ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
JP2000504013A (ja) | 1996-02-01 | 2000-04-04 | スミスクライン・ビーチャム・コーポレイション | エンドセリンレセプターアンタゴニスト |
JP2000507224A (ja) * | 1996-03-08 | 2000-06-13 | スミスクライン・ビーチャム・コーポレイション | Csaid化合物の血管形成の抑制物質としての使用 |
US6096748A (en) * | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
WO1997035856A1 (en) * | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
JP2000507545A (ja) * | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Cns損傷についての新規な治療 |
US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
US5880140A (en) * | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5939557A (en) * | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6080870A (en) * | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
EP0906307B1 (en) * | 1996-06-10 | 2005-04-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
US5854264A (en) | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
IL129928A0 (en) * | 1996-11-19 | 2000-02-29 | Amgen Inc | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US5939439A (en) * | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
DE69816109T2 (de) | 1997-04-24 | 2004-04-22 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte imidazole zur behandlung von entzündlichen krankheiten |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
US6087496A (en) * | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
US6087381A (en) * | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
IL132736A0 (en) * | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
CA2293436C (en) * | 1997-06-12 | 2010-10-26 | Rhone-Poulenc Rorer Limited | Imidazolyl-cyclic acetals as tnf inhibitors |
US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
IL133766A0 (en) * | 1997-06-30 | 2001-04-30 | Ortho Mcneil Pharm Inc | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
TW517055B (en) * | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
US7301021B2 (en) * | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6562832B1 (en) * | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
WO1999032121A1 (en) * | 1997-12-19 | 1999-07-01 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
EP1112070B1 (en) * | 1998-08-20 | 2004-05-12 | Smithkline Beecham Corporation | Novel substituted triazole compounds |
WO2000023444A1 (en) * | 1998-10-21 | 2000-04-27 | Abbott Laboratories | 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds |
JP2002528506A (ja) * | 1998-11-04 | 2002-09-03 | スミスクライン・ビーチャム・コーポレイション | ピリジン−4−イルまたはピリミジン−4−イル置換ピラジン |
US6239279B1 (en) * | 1998-12-16 | 2001-05-29 | Smithkline Beecham Corporation | Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives |
US6288089B1 (en) | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
KR100711538B1 (ko) * | 1998-12-25 | 2007-04-27 | 아스카 세이야쿠 가부시키가이샤 | 아미노피라졸 유도체 |
EP1175419B1 (en) * | 1999-04-02 | 2003-05-28 | Bristol-Myers Squibb Pharma Company | Aryl sulfonyls as factor xa inhibitors |
ES2187473T3 (es) * | 1999-04-09 | 2003-06-16 | Smithkline Beecham Corp | Triarylimidazoles. |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
ES2239596T3 (es) * | 1999-06-03 | 2005-10-01 | Teikoku Hormone Mfg. Co., Ltd. | Compuestos de pirazol sustituidos. |
AU777275B2 (en) * | 1999-07-02 | 2004-10-07 | Stuart A. Lipton | Method of reducing neuronal injury or apoptosis |
US20030109428A1 (en) * | 1999-12-01 | 2003-06-12 | John Bertin | Novel molecules of the card-related protein family and uses thereof |
CO5271715A1 (es) * | 1999-12-21 | 2003-04-30 | Sugen Inc | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa |
EP1289523A1 (en) * | 2000-06-01 | 2003-03-12 | Merck & Co., Inc. | Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors |
CA2409762A1 (en) * | 2000-06-23 | 2002-01-03 | Donald J.P. Pinto | Heteroaryl-phenyl substituted factor xa inhibitors |
GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US7199137B2 (en) * | 2000-09-21 | 2007-04-03 | Smithkline Beecham Plc | Imidazole derivatives as Raf kinase inhibitors |
US6755497B2 (en) * | 2000-09-26 | 2004-06-29 | Canon Kabushiki Kaisha | Ink-jet printing apparatus, control method thereof, and data processing apparatus and method |
JP2002114780A (ja) * | 2000-10-11 | 2002-04-16 | Taisho Pharmaceut Co Ltd | 4−(3−インドリル)イミダゾール誘導体 |
US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
EP1349851A4 (en) * | 2000-11-16 | 2004-09-08 | Smithkline Beecham Corp | COMPOUNDS |
US20040053943A1 (en) * | 2000-11-20 | 2004-03-18 | Adams Jerry L. | Novel compounds |
GB0100762D0 (en) * | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
WO2002066462A1 (en) * | 2001-02-02 | 2002-08-29 | Glaxo Group Limited | Pyrazole derivatives against tgf overexpression |
GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
JP2004521901A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Tgf阻害剤としてのピラゾール |
GB0102665D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
US6727364B2 (en) * | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
WO2002098365A2 (en) * | 2001-06-07 | 2002-12-12 | Skinmedica, Inc. | Conditioned cell culture media and uses thereof |
US7300442B2 (en) * | 2001-07-11 | 2007-11-27 | Daniel Cherfas | Method of destroying formations in a body |
WO2003097615A1 (en) * | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
KR20050057415A (ko) * | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인코포레이티드 | 전환성장인자(tgf) 억제제로서의 신규한 싸이아졸 및 옥사졸 화합물 |
AP2005003264A0 (en) * | 2002-09-18 | 2005-03-31 | Pfizer Prod Inc | Novel imidazole compounds as transforming growth factor (TGD) inhibitors. |
-
2003
- 2003-04-03 AR ARP030101166A patent/AR039241A1/es unknown
- 2003-04-04 UA UA20041108993A patent/UA81624C2/ru unknown
- 2003-04-04 IL IL16429503A patent/IL164295A0/xx unknown
- 2003-04-04 EA EA200401309A patent/EA010418B1/ru not_active IP Right Cessation
- 2003-04-04 NZ NZ536202A patent/NZ536202A/en not_active IP Right Cessation
- 2003-04-04 CA CA002480860A patent/CA2480860A1/en not_active Abandoned
- 2003-04-04 KR KR10-2004-7015706A patent/KR20040094908A/ko not_active Application Discontinuation
- 2003-04-04 WO PCT/US2003/010440 patent/WO2003087304A2/en active Application Filing
- 2003-04-04 JP JP2003584248A patent/JP2005527590A/ja active Pending
- 2003-04-04 US US10/510,459 patent/US7612094B2/en active Active
- 2003-04-04 PL PL03373502A patent/PL373502A1/xx not_active Application Discontinuation
- 2003-04-04 EP EP03726198A patent/EP1499308A4/en not_active Withdrawn
- 2003-04-04 RS YU95904A patent/RS95904A/sr unknown
- 2003-04-04 CN CNB038126990A patent/CN100448868C/zh not_active Expired - Fee Related
- 2003-04-04 AU AU2003228446A patent/AU2003228446B2/en not_active Ceased
- 2003-04-04 MX MXPA04009546A patent/MXPA04009546A/es unknown
-
2004
- 2004-09-28 IS IS7475A patent/IS7475A/is unknown
- 2004-09-30 ZA ZA200407902A patent/ZA200407902B/en unknown
- 2004-11-03 NO NO20044779A patent/NO20044779L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA04009546A (es) | 2005-01-25 |
AU2003228446B2 (en) | 2009-08-06 |
KR20040094908A (ko) | 2004-11-10 |
WO2003087304A3 (en) | 2004-07-22 |
EA200401309A1 (ru) | 2005-08-25 |
JP2005527590A (ja) | 2005-09-15 |
EP1499308A4 (en) | 2006-05-24 |
US7612094B2 (en) | 2009-11-03 |
US20060063809A1 (en) | 2006-03-23 |
WO2003087304A2 (en) | 2003-10-23 |
CN100448868C (zh) | 2009-01-07 |
RS95904A (xx) | 2006-10-27 |
NO20044779L (no) | 2005-01-04 |
IS7475A (is) | 2004-09-28 |
UA81624C2 (ru) | 2008-01-25 |
PL373502A1 (en) | 2005-09-05 |
CN1658866A (zh) | 2005-08-24 |
EA010418B1 (ru) | 2008-08-29 |
EP1499308A2 (en) | 2005-01-26 |
CA2480860A1 (en) | 2003-10-23 |
AR039241A1 (es) | 2005-02-16 |
AU2003228446A1 (en) | 2003-10-27 |
ZA200407902B (en) | 2005-09-22 |
NZ536202A (en) | 2009-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL164295A0 (en) | Tri-substituted heteroaryls and methods of making and using the same | |
EP1546112A4 (en) | IMIDAZOLOPYRIDINE AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
HK1117189A1 (en) | Assay cartridges and methods of using the same | |
AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
AU2003286657A8 (en) | Filters and methods of making and using the same | |
HK1078088A1 (en) | Substituted phenylacetamides and their use as glucokinase activators | |
AU2003275311A1 (en) | Solid micro-perforators and methods of use | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
EP1625140A4 (en) | BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF | |
AU2003259735A8 (en) | Small-mer compositions and methods of use | |
GB0229742D0 (en) | Novel compounds and uses thereof | |
AU2003236991A8 (en) | Representations of processes | |
EP1497270A4 (en) | AMID COMPOUNDS AND METHOD FOR THEIR USE | |
AU2003243714A8 (en) | Etoposide analogs and methods of use thereof | |
PL375699A1 (en) | Pyrazolopyridines and methods of making and using the same | |
AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
EP1476150A4 (en) | CARBOXY FULLERES AND USE METHOD THEREFOR | |
AU2003303926A8 (en) | Ceramics and methods of making the same | |
SI1551805T1 (sl) | Substituirani gama-fenil-delta-laktami in njihova uporaba | |
AU2003275056A8 (en) | Novel lapacho compounds and methods of use thereof | |
EP1484622A4 (en) | PRISM AND CORRESPONDING MANUFACTURING PROCEDURE | |
AU2003297612A8 (en) | 2-substituted-3-propenamide derivatives and methods of using the same | |
EP1545287A4 (en) | VASOREGULATORY COMPOUNDS AND METHODS RELATING TO THEIR USE | |
AU2003276398A8 (en) | Shearwall structure and method of making the same | |
EP1517879A4 (en) | AMINOALKYLPHENOLS AND METHODS OF USE AND MANUFACTURE |